Psoas and pectoralis muscle indices and brown adipose tissue activity may be prognostic indicators in older patients with multiple myeloma.
Yilmaz Kars M., Kars TU., Cayci M., Bagci M., Cirik S., Gunay A.
Retrospective Study, published in Int J Hematol (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Int J Hematol (2026)
- Country
- Japan
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41917308
- DOI
- 10.1007/s12185-026-04206-1
Abstract (original English)
Changes in body composition, particularly sarcopenia and adipose tissue remodeling, have prognostic implications in multiple myeloma (MM). This retrospective study evaluated the prognostic value of PET/CT-derived muscle indices and brown adipose tissue (BAT) activity in 75 MM patients aged ≥ 60 years treated between January 2023 and March 2025. Autologous stem cell transplantation (ASCT) was performed in 41.3% of patients. Median progression-free survival was 6.06 months, with a median follow-up of 25.70 months. ASCT was independently associated with improved overall survival (OR: 0.249, p = 0.060) and a reduced risk of final disease progression (OR: 0.260, p = 0.019). Higher Charlson Comorbidity Index scores independently predicted increased mortality (OR: 1.677, p = 0.017). Reduced skeletal muscle mass, particularly a lower pectoralis major index, was independently associated with disease progression (OR: 0.003, p = 0.012). Among ASCT recipients, higher BAT activity (SUVmean) showed a strong negative correlation with post-transplant progression-free survival (rho = -0.717, p < 0.05). PET/CT-based body composition analysis may provide additional prognostic value in MM.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.